BIOMARCADORES PARA DIAGNÓSTICO DE ENFERMEDAD INFLAMATORIA INTESTINAL

Volver

Resultados 50 resultados LastUpdate Última actualización 20/02/2018 [15:38:00] pdf PDF




Solicitudes publicadas en los últimos 150 días / Applications published in the last 150 days



Página1 de 2 nextPage   Mostrar por página


METHODS OF DETECTING INFLAMMATORY MARKERS AND TREATING INFLAMMATORY CONDITIONS IN HUMANS

NºPublicación: US2018045724A1 15/02/2018

Solicitante:
VETICA LABS INC [US]

Resumen de: US2018045724A1

The present invention provides methods and systems to accurately detect and measure in a biological sample from a patient, endogenous antibodies, e.g., IgA, to inflammatory proteins, which antibodies are useful as diagnostic markers for inflammatory conditions, including bowel disease (IBD), in patients. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.



traducir


 

ANTIGENS ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE

NºPublicación: US2018044408A1 15/02/2018

Solicitante:
PHILOGEN SPA [IT]

Resumen de: US2018044408A1

Specific binding members that bind the ED-A isoform of fibronectin for use in methods of treatment, diagnosis, detection and/or imaging of inflammatory bowel disease (IBD), and/or for use in delivery to the IBD tissue of a molecule conjugated to the specific binding member. The specific binding member may, for example, be conjugated to an immunosupressive or anti-inflammatory molecule, such as interleukin-10.



traducir


 

Ulcerative Colitis (UC)-Associated Colorectal Neoplasia Markers

NºPublicación: US2018030545A1 01/02/2018

Solicitante:
BAYLOR RES INSTITUTE [US]

Resumen de: US2018030545A1

Embodiments provide methods and compositions related to detecting neoplasia in ulcerative colitis patients by detection and analysis of the methylation state of miR-1, -9, -124, miR-137 and/or miR-34b/c in samples from UC patients.



traducir


 

BIOMARKER

NºPublicación: US2018022800A1 25/01/2018

Solicitante:
ISIS INNOVATION [GB]

Resumen de: US2018022800A1

The invention relates to methods of treating chronic intestinal inflammation and/or inflammatory bowel disease by administering an antagonist of oncostatin-M (OSM) and/or OSM receptor-β (OSMR). The invention also relates to methods for diagnosing or prognosing chronic intestinal inflammation and/or inflammatory bowel disease in an individual and for predicting whether or not an individual will respond to an anti-TNFα therapy. The methods comprise measuring OSM and/or OSMR in the individual.



traducir


 

KITS AND METHODS FOR DETECTING AND TREATING GASTROINTESTINAL DISORDERS AND INFECTIONS

NºPublicación: WO2018017880A1 25/01/2018

Solicitante:
MAN REVENUE GROUP P R LLC [US]

Resumen de: WO2018017880A1

Provided are methods for the detection of an infectious disease, an infection, or a condition related to the presence of a microbe in an individual in need thereof to provide individualized identification of a microbial profile in the individual, and for providing a guidance for a treatment regimen for the individual. In alternative embodiments, the GI infections, diseases and conditions detected by products of manufacture, including kits, and methods as provided herein include Crohn's disease, Inflammatory Bowel Disease (IBD), ulcers, celiac disease, intestinal disorders, and other gastrointestinal related functional or metabolic disorders.



traducir


 

PREDICTIVE MARKERS OF IBD

NºPublicación: US2018024149A1 25/01/2018

Solicitante:
NESTEC SA [CH]

Resumen de: US2018024149A1

The invention relates to a method, a system and kit for identifying the sample of a patient having IBD or predicting the relapse of IBD in patients based on the measurement of biomarkers in a sample of the patient. The biomarkers can be lipids or amino acids or a combination thereof.



traducir


 

METHOD FOR DETECTING METHYLATION OF COLORECTAL CANCER SPECIFIC METHYLATION MARKER GENE FOR COLORECTAL CANCER DIAGNOSIS

NºPublicación: US2018016644A1 18/01/2018

Solicitante:
GENOMICTREE INC [KR]

Resumen de: US2018016644A1

The present disclosure relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present disclosure can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.



traducir


 

Method of treating Crohn's disease

NºPublicación: AU2016279911A1 18/01/2018

Solicitante:
MURDOCH CHILDRENS RES INSTITUTE
ST VINCENT \u0301S HOSPITAL MELBOURNE

Resumen de: AU2016279911A1

The invention relates to the treatment of inflammatory bowel disease characterised by chronic inflammation. In particular, the invention relates to methods of predicting, treating or preventing post-operative recurrence of Crohn's disease.



traducir


 

MULTIPLEXED ASSAY KIT TO EVALUATE THE EFFICACY OF TREATMENT FOR INFLAMMATORY BOWEL DISEASE

NºPublicación: US2018017578A1 18/01/2018

Solicitante:
MESO SCALE TECHNOLOGIES LLC [US]

Resumen de: US2018017578A1

Disclosed are methods for conducting diagnostic tests for the detection of the inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis. Also described are methods for monitoring a patient by administering tests of the present invention. Also described are methods for monitoring patient's treatment by administering tests of the present invention. Also described are methods for evaluating the effectiveness of a drug or a drug candidate by administering tests of the present invention to samples from patients, animal models, and cell cultures treated with a drug or a drug candidate. Also disclosed are methods for determining the usefulness of analytes, e.g. cytokines, for acting as diagnostic and monitoring markers for inflammatory bowel disease in the various methods of the invention.



traducir


 

BIOMARKERS FOR INFLAMMATORY BOWEL DISEASE

NºPublicación: WO2018007872A1 11/01/2018

Solicitante:
CAMBRIDGE ENTERPRISE LTD [GB]

Resumen de: WO2018007872A1

The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.



traducir


 

Biomarkers for Inflammatory Bowel Disease

NºPublicación: US2018010187A1 11/01/2018

Solicitante:
CAMBRIDGE ENTERPRISE LTD [GB]

Resumen de: US2018010187A1

The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.



traducir


 

Biomarkers for Inflammatory Bowel Disease

NºPublicación: US2018010189A1 11/01/2018

Solicitante:
CAMBRIDGE ENTERPRISE LTD [GB]

Resumen de: US2018010189A1

The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.



traducir


 

METHOD FOR DETERMINING POSSIBILITY OF ONSET OF COLON CANCER

NºPublicación: WO2018008153A1 11/01/2018

Solicitante:
HANUMAT CO LTD [JP]
EA PHARMA CO LTD [JP]

Resumen de: WO2018008153A1

The present invention is a method for determining the possibility of the onset of colon cancer in human ulcerative colitis patients, wherein the method for determining the possibility of onset of colon cancer includes a measurement step for measuring the methylation rate of one or more CpG sites selected from the group consisting of CpG sites in base sequences represented by SEQ ID NOS: 1-80 in DNA recovered from a biological sample collected from a human ulcerative colitis patient, and a determination step for determining the possibility of onset of colon cancer in the human ulcerative colitis patient on the basis of the methylation rate measured in the measurement step and a preset reference value or preset multivariate discriminant.



traducir


 

METHOD FOR JUDGING ONSET POSSIBILITY OF LARGE BOWEL CANCER

NºPublicación: WO2018008740A1 11/01/2018

Solicitante:
HANUMAT CO LTD [JP]
EA PHARMA CO LTD [JP]

Resumen de: WO2018008740A1

The present invention provides a method for judging the onset possibility of large bowel cancer in a human ulcerative colitis patient, etc. The method comprises a measurement step for measuring methylation ratios at one or more CpG sites existing in specific differentially methylated regions in DNA collected from a biological sample that is obtained from the human ulcerative colitis patient, and a judgment step for judging the onset possibility of large bowel cancer in the human ulcerative colitis patient on the basis of the average methylation ratio of the differentially methylated regions, said average methylation ratio being calculated from the measured methylation ratios, and preset standard values or a preset multivariable discriminant, wherein: the standard values are values having been set for the methylation ratios in the respective differentially methylated regions for discriminating a cancerous ulcerative colitis patient from a non-cancerous ulcerative colitis patient; and the multivariable discriminant contains, as variables, the average methylation ratios at one or more differentially methylated regions among the specific differentially methylated regions.



traducir


 

IGFBP3 and uses thereof

NºPublicación: AU2016272044A1 04/01/2018

Solicitante:
OSPEDALE SAN RAFFAELE SRL

Resumen de: AU2016272044A1

The present invention relates to an inhibitor of IGFBP3 and uses thereof for the treatment and/or prevention of an intestinal disease, in particular of diabetic enteropathy or inflammatory bowel disease. The present invention also relates to IGFBP3 and uses thereof for the diagnosis, prognosis or an intestinal disease, in particular of diabetic enteropathy or inflammatory bowel disease.



traducir


 

BIOMARKER FOR DIAGNOSING INFLAMMATORY DISEASES

NºPublicación: WO2018002564A1 04/01/2018

Solicitante:
IP RES CONSULTING [FR]

Resumen de: WO2018002564A1

The invention relates to the use of a biomarker for diagnosing an inflammatory disease, in particular a chronic inflammatory disease and specifically chronic inflammatory bowel diseases, a diagnostic method, a method for assessing the efficacy of a treatment, an assay method, as well as kits and enzyme substrates.



traducir


 

TREATMENT OF TH17 MEDIATED INFLAMMATORY DISEASES

NºPublicación: US2017369885A1 28/12/2017

Solicitante:
GENENTECH INC [US]

Resumen de: US2017369885A1

The present invention provides methods and means to reduce inflammation associated with IRF-4, AP-1 and TH17 mediated diseases. In particular, the invention provides methods and means to treat multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease, and psoriasis and related conditions.



traducir


 

DIAGNOSTIC AND THERAPEUTIC METHODS RELATED TO INFLAMMATORY BOWEL DISEASES

NºPublicación: WO2017223409A1 28/12/2017

Solicitante:
THE SCRIPPS RES INSTITUTE [US]

Resumen de: WO2017223409A1

The present invention provides methods and compositions for monitoring MDR1 transporter function in human IBD patients. Also provided in the invention are methods for stratification of IBD patients for bile acid directed therapies, and therapeutic methods that integrate the patient stratification with bile acid sequestration therapies.



traducir


 

FOOD INGREDIENTS PRODUCED FROM HIGH AMYLOSE WHEAT

NºPublicación: US2017367382A1 28/12/2017

Solicitante:
REGINA AHMED [AU]
MORELL MATTHEW KENNEDY [AU]
BERBEZY PIERRE GEORGES LOUIS [FR]
CHANLIAUD ELISABETH MARIE-ANNE IDA [FR]
DUPERRIER BERNARD [FR]
ARISTA CEREAL TECH PTY LIMITED [AU]

Resumen de: US2017367382A1

Provided are food and drink ingredients produced from wheat grain which has a low level (2-30%) of total starch branching enzyme II activity and an amylose content in the starch of at least 50% (w/w), and processes for producing and using the ingredients. Also provided are foods produced from the ingredients which may be used in humans to improve one or more parameters of metabolic health, bowel health or cardiovascular health.



traducir


 

PROBIOTIC ORGANISMS FOR DIAGNOSIS, MONITORING, AND TREATMENT OF INFLAMMATORY BOWEL DISEASE

NºPublicación: US2017360850A1 21/12/2017

Solicitante:
MASSACHUSETTS INSTITUTE OF TECH [US]
SYNLOGIC INC [US]

Resumen de: US2017360850A1

Aspects of the present disclosure relate to genetically engineered organisms useful for the diagnosis and treatment of inflammatory bowel disease.



traducir


 

CD1A AS THERAPEUTIC TARGET MOLECULE AND DIAGNOSTIC MARKER FOR INFLAMMATORY BOWEL DISEASES

NºPublicación: WO2017216253A1 21/12/2017

Solicitante:
KLINIKUM DER UNIVERSIT\u00C4T M\u00DCNCHEN [DE]

Resumen de: WO2017216253A1

The present invention relates to the identification of a novel therapeutic target and diagnostic marker of chronic inflammatory bowel diseases, such as Colitis ulcerosa (UC) or Crohn' Disease (CD). The novel diagnostic marker can be used to monitor treatment efficacy and/or disease stage. This marker is the lipid receptor CD1a, which is a transmembrane glycoprotein present on antigen presenting cells (APC), and mediates the presentation of primarily lipid and glycolipid antigens to T cells. CD1a can also be used as a therapeutic target molecule, as blocking of this receptor will result in a decrease of the inflammatory process mediated by the T cells activated by the presentation of the antigen by APCs. This blocking can for example be achieved by anti CD1a-specific antibodies, or by the use of inhibitory lipids or small inhibitory molecules.



traducir


 

METHODS FOR PREDICTING ACUTE SEVERE COLITIS TREATMENT RESPONSE

NºPublicación: WO2017216206A1 21/12/2017

Solicitante:
INSERM (INSTITUT NATIONAL DE LA SANT\u00C9 ET DE LA RECH M\u00C9DICALE) [FR]
UNIVERSIT\u00C9 PARIS DIDEROT - PARIS 7 [FR]
ASSIST PUBLIQUE-H\u00D4PITAUX DE PARIS (APHP) [FR]
UNIVERSIT\u00C9 DE BORDEAUX [FR]
CHU H\u00D4PITAUX DE BORDEAUX [FR]
UNIVERSIT\u00C9 PARIS XIII PARIS-NORD [FR]

Resumen de: WO2017216206A1

The present invention relates to methods for predicting acute severe colitis treatment response. Currently, there is no biomarker of drug response. The present invention provides the first prediction tool for responses to first- and second-line treatments in acute severe ulcerative colitis. Putative mRNA targets of dysregulated microRNAs were identified from patient biopsies. One classifier of fifteen colonic microRNAs plus five biological values at admission were identified with a prediction accuracy of 96.6% for discriminating responders from non-responders to steroids. Using a similar method, 6 and 4 mucosal microRNA-based algorithms were identified to classify responders from non-responders to infliximab and cyclosporine. In particular, the present invention relates to methods for predicting acute severe colitis treatment response by measuring the expression levels of several miRNAs selected from the group consisting of hp_hsa-mir-3934, hp_hsa-mir-100, hsa-miR-718, hp_hsa-mir-193b, hsa-miR-3150a-5p, hp_hsa-mir-1260b, hsa-miR-938, hsa-miR-518b and hsa-miR-1468.



traducir


 

METHOD OF TREATMENT OF GUT INFLAMMATORY DISEASES SUCH AS INFLAMMATORY BOWEL DISEASES (IBD) OR IRRITABLE BOWEL SYNDROME (IBS)

NºPublicación: WO2017216352A1 21/12/2017

Solicitante:
INSERM (INSTITUT NATIONAL DE LA SANT\u00C9 ET DE LA RECH M\u00C9DICALE) [FR]
UNIVERSIT\u00C9 PAUL SABATIER TOULOUSE III [FR]
CENTRE NATIONAL DE LA RECHERCHE SCIENT (CNRS) [FR]

Resumen de: WO2017216352A1

The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.



traducir


 

2B4CD244 Use of 2B4CD244 for Diagnosing and Treating Inflammatory Bowel Disease

NºPublicación: KR20170139461A 19/12/2017

Solicitante:
KOREA UNIV RESEARCH AND BUSINESS FOUNDATION [KR]

Resumen de: KR20170139461A

본 발명은 면역세포 수용체인 2B4(CD244)의 염증성 장질환 진단 및 치료제로서의 용도에 관한 것으로, 구체적으로는 2B4 유전자의 발현수준 또는 2B4 단백질의 수준을 측정할 수 있는 물질을 함유하는 염증성 장질환 진단용 조성물 및 2B4를 코딩하는 유전자를 함유하는 재조합벡터 또는 2B4 단백질을 유효성분으로 포함하는 염증성 장질환 치료용 약학 조성물에 관한 것이다. 본 발명의 조성물을 이용하면 염증성 장질환을 신속하고 정확하게 진단할 수 있고, 빈번한 배변과 출혈, 체중 감소, 결장 길이 감소와 같이 일상 생활에 과도한 고통을 수반하는 염증성 장질환을 효과적으로 치료할 수 있다.



traducir


 

BIOMARKERS FOR PLATELET DISORDERS

Nº publicación: WO2017208001A1 07/12/2017

Solicitante:
BABRAHAM INST [GB]

Resumen de: WO2017208001A1

The invention relates to novel targets and biomarkers for the diagnosis and treatment of selected diseases or disorders, in particular blood disorders (such as platelet disorders and red blood cell disorders), autoimmune disorders (such as ulcerative colitis, multiple sclerosis, rheumatoid arthritis, celiac disease and Crohn's disease), diabetes (such as Type 1 diabetes and Type 2 diabetes), height/growth disorders, disorders related to lipid metabolism, disorders related to glucose metabolism, disorders related to insulin metabolism, disorders related to bone mineral density, disorders related to blood pressure and disorders related to body mass index. The invention also relates to methods of diagnosing said diseases or disorders and methods of screening of modulators said biomarkers.


traducir



 

Página1 de 2 nextPage Mostrar por página

Volver